Humanized liver chimeric mouse

Hepatocyte chimeric mice, where human liver cells engraft into mouse livers, are gaining attention as an innovative model to overcome the hurdles in drug discovery posed by interspecies differences. This technology, capable of replicating human-like metabolism, infection responses, and toxicity reactions *in vivo*, serves as a crucial evaluation platform that influences the success rate of new drug development. This article systematically organizes everything from the fundamentals to the latest trends and practical utilization strategies.

Reproducing "Humanoid Metabolism" to overcome species differences

Humanized liver chimeric mice areA model that can reproduce "human-type metabolism" within the body, overcoming species differences, by engrafting human hepatocytes into mouse livers.In new drug development, species differences in drug-metabolizing enzymes (CYPs) and transporters pose significant hurdles. However, this model enables the evaluation of ADME (Absorption, Distribution, Metabolism, Excretion) characteristics that are close to those in humans. Furthermore, in addition to safety testing, it is applied to research on Hepatitis B and C viruses, which infect only human liver cells, playing a crucial role as the gold standard in drug discovery research.

Standard Review: Establishment and Validation of Technology

To substantiate their utility, humanized liver chimeric mice have undergone a phased development of established techniques and verification of their reproducibility and reliability. Here, representative papers concerning the refinement of model construction methods, functional evaluation, and validation of pharmacokinetics and infectivity are discussed to provide an overview of their validity and practicality.

[Classic 1] The uPA/SCID Model and the Concept of Replacement Rate

• Paper title: Generation of humanized liver in mice by means of wet-lab based techniques and its applications.
• Author/Journal: Tateno C, et al. / American Journal of Pathology, etc.

Pioneering papers that laid the foundation for research on humanized liver chimeric miceWe demonstrated that a high rate of hepatocyte replacement can be achieved by transplanting human hepatocytes into SCID mice in which liver injury was induced by uPA (urokinase-type plasminogen activator) gene transfer. Furthermore, we have demonstrated that human CYP enzymes are functionally expressed in the mouse body, thereby reproducing human-specific drug metabolism. This study is essential reading for practitioners as it establishes the evaluation index of "replacement rate" and presents a standard framework for subsequent model development and pharmacokinetic testing.

[Standard 2] Usefulness in Pharmacokinetic (PK) Prediction

• Paper Title: Chimeric mice with humanized liver: a unique tool for predicting drug metabolism, toxicity, and safety in humans.
• Author/Journal: Katoh M, et al. / Current Drug Metabolism

A paper systematically demonstrating the usefulness of humanized liver chimeric mice in predicting pharmacokinetics.This model has confirmed functionality of human CYP enzymes and transporters, enabling the in vivo reproduction of metabolic profiles close to those in humans. It demonstrates high predictability, particularly in evaluating the generation and clearance of human-specific metabolites and detecting safety signals, thereby overcoming species differences that are challenging with conventional animal models. It contributes to improved accuracy in PK/toxicity assessments during the preclinical stage and is positioned as a practical tool for acquiring data with high human extrapolability.

Latest Review: Next-Generation Models and New Applications (2024-2026)

Recent reviews indicate that humanized liver cell chimeric mice are rapidly expanding their applications beyond traditional drug metabolism evaluation to RNA therapeutics, gene therapy, and models for immune and metabolic diseases. Here we introduce the latest review.

[Trend 1] Expansion to NASH/MASH and Fibrosis Models

• Key points: Attempt to replicate human-like pathology (fatty liver, inflammation, fibrosis) by feeding high-fat diets to mice engrafted with human hepatocytes.
• Latest Trends: Advances in Humanized Mouse Models for Metabolic Liver Diseases (Around 2025)

Advances in metabolic liver disease models using humanized liver chimeric mice are organized.By feeding mice engrafted with human liver cells a high-fat or high-sugar diet, a series of pathological conditions, including fat accumulation, inflammation, and even fibrosis, can be reproduced in a manner similar to humans.A key point is that they reflect human-specific lipid metabolism and lipoprotein kinetics, which were previously poorly represented in traditional rodent models. Therefore, they show high utility in evaluating the efficacy of therapeutic drugs for MASH (metabolic dysfunction-associated steatohepatitis) and in searching for biomarkers. Furthermore, these models enable longitudinal analysis of disease progression and interventional studies targeting human-specific molecules, positioning them as next-generation models that accelerate both the understanding of pathophysiology and drug discovery.

[Trend 2] Evaluation Platform for Gene Therapy and Nucleic Acid Drugs

• Key point: Confirmation of tropism of AAV (Adeno-associated virus) vectors to human hepatocytes.
• Latest development: Verification of gene transduction efficiency specific to human hepatocytes.

With AAV vector tropism as a focus, humanized liver chimeric mice are gaining attention as a core model for gene therapy evaluation. This model allows for direct in vivo verification of the extent to which AAV (adeno-associated virus) vectors selectively infect and express in human hepatocytes.Precise evaluation of human-specific directionality and introduction efficiency is possible.In recent years, applications for optimizing the delivery of nucleic acid therapeutics such as capsid-modified AAV, siRNA, and mRNA have been advancing, with simultaneous analysis of expression levels, durability, and safety profiles in human hepatocytes. This next-generation platform is gaining importance as it enables the acquisition of highly clinically translatable data, addressing challenges such as human-specific transduction differences and off-target effects that were difficult to assess with conventional models.

Disease Area Specific Major Review List

Humanized liver chimeric mice are selected with optimal strains depending on their application, and the evaluation axes differ for each disease area. Recent reviews have organized the characteristics and limitations of models for major areas such as PK/ADME, infectious diseases, toxicity, and gene therapy, emphasizing the importance of using them appropriately based on their suitability for the intended purpose.

Strategic perspective

Regarding the strategic utilization of humanized liver chimeric mice, the key to increasing confidence in seeds primarily focuses on two points. First is the selection of donor hepatocytes,Differences in CYP expression, metabolic capacity, and genetic background directly impact data interpretation.Therefore, appropriate donor selection for the purpose is essential. Second, development towards dual humanized models that humanize not only the liver but also the immune system.This allows for more clinically relevant evaluations, including inflammatory response and immune-mediated toxicity.This leads to designs that contribute to improved accuracy in drug discovery decision-making.

Summary

Humanized liver chimeric mice have been widely utilized for a range of applications, including PK/ADME evaluation, viral research, toxicity testing, and gene therapy assessment, due to their ability to reproduce human-like metabolism across species differences. In recent years, their application has expanded to areas such as NASH/MASH and nucleic acid-based drugs, evolving into a core platform for drug discovery. Despite challenges such as high cost and difficulty in breeding, they play an extremely important role in preventing unexpected hepatotoxicity-related dropouts in clinical trials.